Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi

Digital Clinical Trial Collaboration Expands to Multiple Sclerosis

News provided by

Koneksa Inc.

03 Nov, 2021, 08:00 ET

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Koneksa, the leader in developing and implementing patient-centric digital biomarkers for drug development, today announced that Sanofi, one of the world's top biopharmaceutical companies, has extended the two companies' collaboration in central nervous system (CNS) clinical trials.

"We're proud that our long-term partnership has enabled Sanofi's deployment of digital measures across multiple therapeutic areas and modalities," said Chris Benko, Koneksa's CEO. "This project leverages learnings from our collaboration on Parkinson's Disease into multiple sclerosis, another devastating neurological disease that badly needs new treatment options."

Koneksa's work with Sanofi will support the investigation of tolebrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, which is an oral, brain-penetrant, selective small molecule currently in Phase III trials for all MS subtypes including Primary Progressive MS (PPMS), Relapsing MS (RMS) and non-relapsing Secondary Progressive MS (nrSPMS).  MS affects almost three million people worldwide, and patients with progressive MS experience a steady evolution of the disease with no remissions.

"Digital endpoints in clinical trials make it possible for researchers to gain insights that were never before within our reach," said Rob Ellis, Ph.D., Head of Data Science at Koneksa. "We're excited for Sanofi to continue incorporating Koneksa's digital biomarker platform into their CNS research." 

About Koneksa
Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research. Learn more at koneksahealth.com.

Media Contact
Katy Keating, Sagefrog Marketing Group
[email protected] 
302-740-0766

SOURCE Koneksa Inc.

Related Links

http://koneksahealth.com

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.